Laboratory biomarkers in the diagnosis and follow-up of treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis

Steels, Sophie; Proesmans, Marijke; Bossuyt, Xavier; Dupont, Lieven; Frans, Glynis

doi:10.1080/10408363.2022.2101612

Cited by 3 publications

(5 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…93 Existing diagnostic criteria, such as the CF Foundation (CFF) criteria for pwCF 94 or the Agarwal criteria for pwA, 95 rely on the combination of clinical signs and symptoms, chest radiography or computed tomography, and the presence of biomarkers such as total and Aspergillus -specific IgE and IgG. 91 96 Nevertheless, these combined criteria remain nonspecific, rendering the diagnosis of ABPA challenging. 94 96 ABPA is preceded by Aspergillus sensitization, which has a prevalence varying from 20 to 65% in pwCF.…”

Section: Allergic Manifestations: Misdirected Acquired Immunity Towar...mentioning

confidence: 99%

“…91,96 Nevertheless, these combined criteria remain nonspecific, rendering the diagno-sis of ABPA challenging. 94,96 ABPA is preceded by Aspergillus sensitization, which has a prevalence varying from 20 to 65% in pwCF. 92 Both the European CF Society and the United States CFF recommend annual screening for Aspergillus sensitization and ABPA.…”

Section: Allergic Bronchopulmonary Aspergillosismentioning

confidence: 99%

See 1 more Smart Citation

Aspergillus and the Lung

Janssens,

Lambrecht,

Van Braeckel

2024

Semin Respir Crit Care Med

View full text Add to dashboard Cite

The filamentous fungus Aspergillus causes a wide spectrum of diseases in the human lung, with Aspergillus fumigatus being the most pathogenic and allergenic subspecies. The broad range of clinical syndromes that can develop from the presence of Aspergillus in the respiratory tract is determined by the interaction between host and pathogen. In this review, an oversight of the different clinical entities of pulmonary aspergillosis is given, categorized by their main pathophysiological mechanisms. The underlying immune processes are discussed, and the main clinical, radiological, biochemical, microbiological, and histopathological findings are summarized.

show abstract

Section: Allergic Manifestations: Misdirected Acquired Immunity Towar...mentioning

confidence: 99%

Section: Allergic Bronchopulmonary Aspergillosismentioning

confidence: 99%

Aspergillus and the Lung

Janssens,

Lambrecht,

Van Braeckel

2024

Semin Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

“…ABPA can present without any radiological manifestations, emphasizing that the diagnosis of ABPA is primarily immunological. Radiologic classification of ABPA following the immunological laboratory criteria are: 7 79 83 84 85…”

Section: Allergic Bronchopulmonary Aspergillosismentioning

confidence: 99%

“…We should not forget this because relying solely on a single diagnostic field, we will not get a complete diagnostic and clinical answer. 40 85 114 Resistance testing is crucial, not only because of increasing resistance to azole antifungals but also because of the presence of cryptic species with known resistance patterns (e.g., reported as A. fumigatus complex), which are not possible to identify using classical identification methods. 105 115…”

Section: Laboratory Diagnosis Of Aspergillus Spp Infe...mentioning

confidence: 99%

Pulmonary Aspergillosis in People with Cystic Fibrosis

Schwarz,

Eschenhagen,

Mainz

et al. 2024

Semin Respir Crit Care Med

View full text Add to dashboard Cite

In the last decade, fungal respiratory diseases have been increasingly investigated for their impact on the clinical course of people with cystic fibrosis (CF), with a particular focus on infections caused by Aspergillus spp. The most common organisms from this genus detected from respiratory cultures are Aspergillus fumigatus and Aspergillus terreus, followed by Aspergillus flavus, Aspergillus niger, and Aspergillus nidulans. These species have been identified to be both chronic colonizers and sources of active infection and may negatively impact lung function in people with CF. This review article discusses definitions of aspergillosis, challenges in clinical practice, and current literature available for laboratory findings, clinical diagnosis, and treatment options for pulmonary diseases caused by Aspergillus spp. in people with CF.

show abstract

“…[1][2][3] Non-invasive infections in immunocompetent patients with underlying pulmonary conditions can lead to chronic pulmonary aspergillosis (CPA), and others can suffer from allergic bronchopulmonary aspergillosis (ABPA), fungal asthma, and Aspergillus bronchitis. [4][5][6] A. fumigatus has been identified as a critical priority fungal pathogen in the first-ever fungal priority pathogen list released by the World Health Organization (WHO) (https://www.who.int/publications/i/item/9789240060241). Recently, there has been a rise in reported cases of IA in patients with influenza 7 and coronavirus disease 2019 (COVID-19).…”

Section: Introductionmentioning

confidence: 99%

Epidemiology and Azole Resistance of Clinical Isolates of Aspergillus fumigatus from a Large Tertiary Hospital in Ningxia, China

Kang,

Li,

Yao

et al. 2024

IDR

View full text Add to dashboard Cite

Purpose The objective of this study was to determine the clinical distribution, in vitro antifungal susceptibility and underlying resistance mechanisms of Aspergillus fumigatus ( A. fumigatus ) isolates from the General Hospital of Ningxia Medical University between November 2021 and May 2023. Methods Antifungal susceptibility testing was performed using the Sensititre YeastOne YO10, and isolates with high minimal inhibitory concentrations (MICs) were further confirmed using the standard broth microdilution assays established by the Clinical and Laboratory Standards Institute (CLSI) M38-third edition. Whole-Genome Resequencing and RT-qPCR in azole-resistant A. fumigatus strains were performed to investigate the underlying resistance mechanisms. Results Overall, a total of 276 A. fumigatus isolates were identified from various clinical departments, showing an increasing trend in the number of isolates over the past 3 years. Two azole-resistant A. fumigatus strains (0.72%) were observed, one of which showed overexpression of cyp51A, cyp51B, cdr1B, MDR1/2, artR, srbA, erg24A , and erg4B , but no cyp51A mutation. However, the other strain harbored two alterations in the cyp51A sequences (L98H/S297T). Therefore, we first described two azole-resistant clinical A. fumigatus strains in Ningxia, China, and reported one azole-resistant strain that has the L98H/S297T mutations in the cyp51A gene without any tandem repeat (TR) sequences in the promoter region. Conclusions This study emphasizes the importance of enhancing attention and surveillance of azole-resistant A. fumigatus , particularly those with non-TR point mutations of cyp51A or non- cyp51A mutations, in order to gain a better understanding of their prevalence and spread in the region.

show abstract

Laboratory biomarkers in the diagnosis and follow-up of treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis

Cited by 3 publications

References 140 publications

Aspergillus and the Lung

Aspergillus and the Lung

Pulmonary Aspergillosis in People with Cystic Fibrosis

Epidemiology and Azole Resistance of Clinical Isolates of Aspergillus fumigatus from a Large Tertiary Hospital in Ningxia, China

Contact Info

Product

Resources

About